Skip to content
Innovex Therapeutics
  • Home
  • R&D
    • Vaccine against Plasmodium vivax malaria
    • Vaccine against Covid-19
    • Vaccine against PRRSV
  • About Us
    • The company
    • Our Story
    • The Team
    • Advisory board
  • News
  • Contact Us
  • Home
  • R&D
    • Vaccine against Plasmodium vivax malaria
    • Vaccine against Covid-19
    • Vaccine against PRRSV
  • About Us
    • The company
    • Our Story
    • The Team
    • Advisory board
  • News
  • Contact Us
Innovex Therapeutics
  • Home
  • R&D
    • Vaccine against Plasmodium vivax malaria
    • Vaccine against Covid-19
    • Vaccine against PRRSV
  • About Us
    • The company
    • Our Story
    • The Team
    • Advisory board
  • News
  • Contact Us
  • Home
  • R&D
    • Vaccine against Plasmodium vivax malaria
    • Vaccine against Covid-19
    • Vaccine against PRRSV
  • About Us
    • The company
    • Our Story
    • The Team
    • Advisory board
  • News
  • Contact Us

ITSL makes a remarkable advance in exosome-based PRRSV vaccine development

Recently, research conducted by the ITSL R&D team have culminated with the publication of a research article in the prestigious journal Veterinary Research (Montaner-Tarbes et al. – 2016)

Continue reading

Recent Posts

  • The Plasmodium vivax malaria project of ITSL elected as part the fund’s portfolio of the EU Malaria Fund
  • Plasmodium vivax: the Neglected Malaria
  • Dr. Agustin Arasanz Duque named new Interim CEO of ITSL
  • RIS3CAT Project
  • New shareholders

Search Content

Navigation

  • Home
  • R&D
    • Vaccine against Plasmodium vivax malaria
    • Vaccine against Covid-19
    • Vaccine against PRRSV
  • About Us
    • The company
    • Our Story
    • The Team
    • Advisory board
  • News
  • Contact Us

Today’s Choice

Follow Us

DribbbleSpotifySteamWeiboPinterest
Innovex Therapeutics
Innovex Therapeutics S.L. is a biotechnology company that uses Extracellular Vesicles as Vaccines against infectious diseases with the goal of global health equity.
Linkedin